Drug Profile
TAK 100
Alternative Names: TAK-100Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Takeda
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 21 May 2010 Discontinued - Phase-I for Type-2 diabetes mellitus in Japan (PO)
- 06 May 2010 TAK 100 is still in phase I trials for Type-2 diabetes in Japan
- 31 Jan 2008 Phase-I clinical trials in Type-2 diabetes mellitus in Japan (PO)